PhD Candidate Calum Leitch

MS in molecular and cellular biology from the University of Glasgow in 2012. Since 2012 he has been a PhD candidate in the Gjertsen group, focusing on the identification and repurposing of approved medicines for therapy development in acute myeloid leukemia. Particular emphasis is placed on mechanistic studies to determine likely responders in patient sub-groups.